Treatment of Secondary Hyperparathyroidism: Results of a Phase 2 Trial Evaluating an Intravenous Peptide Agonist of the Calcium-Sensing Receptor
Conclusion: AMG416 was well tolerated and appears to be an effective agent for the treatment of SHPT in patients on hemodialysis.Am J Nephrol 2015;42:379-388
Source: American Journal of Nephrology - Category: Neurology Source Type: research
More News: Calcium | Dialysis | Hemodialysis | Hormones | Hyperparathyroidism | Neurology | Study | Urology & Nephrology